Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as oral tablets for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. The medication works by modulating neurotransmitter activity, helping to alleviate depressive symptoms such as low mood, loss of interest, and impaired concentration.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union GMP standards and provides reliable logistics for global distribution, ensuring product integrity from manufacturing to end‑user.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes in adult patients.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction - Seizures - Suicidal thoughts or behavior - Severe allergic reactions such as anaphylaxis

Before initiating therapy, several safety considerations should be reviewed. - Assess psychiatric history: evaluate risk of suicidal ideation, especially in early treatment. - Monitor weight and metabolic parameters: mirtazapine can increase appetite and cause weight gain. - Review hepatic function: dose adjustment may be needed in severe liver impairment. - Caution in patients with a history of seizures or hematologic disorders. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; a 14‑day washout is required. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Anticholinergic medications: increased anticholinergic burden may exacerbate dry mouth and constipation. - Alcohol: enhances sedative effects and may impair cognition.